New PharmGKB pathways for methylphenidate

PharmGKB released two new pathways for methylphenidate. Methylphenidate is a central nervous system stimulant used for the treatment of attention deficit hyperactivity disorder and narcolepsy and elicits its effects by blocking the reuptake of the neurotransmitter dopamine and norepinephrine into the presynaptic neuron. The pharmacokinetics pathway depicts the metabolism and the pharmacodynamics pathway describes the synthesis, degradation, release and uptake of monoamines, synaptic effectors and targets of methylphenidate. Both summaries discuss the effect of genetic variations on methylphenidate.View all pathways at PharmGKB

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.